HAEMONETICS CORP 8-K

What Happened
Haemonetics Corporation (filed 8-K June 5, 2026) announced it is changing its reportable segment structure to match how the company manages the business. Beginning with the first quarter of fiscal 2027 the prior Plasma and Blood Center segments will be combined into a single reportable segment called "Apheresis," and the Hospital segment will be renamed "MedSurg." The company issued a press release and posted a supplemental presentation on its Investor Relations website that includes quarterly historical reconciliations and a recast of its previously issued fiscal 2027 guidance in the new segment structure. The 8-K was signed by President and CEO Christopher A. Simon.

Key Details

• Announcement date: June 5, 2026 (8-K filed same day).
• New segment structure effective: beginning Q1 FY2027.
• Segments changed: Plasma + Blood Center → combined as "Apheresis"; Hospital → renamed "MedSurg."
• Supplemental materials: presentation with quarterly reconciliations from Q1 FY2024 through Q4 FY2026 and a recast of FY2027 guidance posted on www.haemonetics.com.
• Guidance status: the company is not reaffirming or updating its prior FY2027 guidance; any updates will be provided on the Company’s Q1 FY2027 earnings call.

Why It Matters
This is a reporting and presentation change intended to align external financial reporting with internal management and resource allocation. Investors should note that historical segment results have been recast for comparability, and the company has republished guidance in the new segment format but has not changed or reaffirmed the underlying FY2027 guidance. Watch the Q1 FY2027 earnings call for any updates and to see how the new segment reporting may affect future revenue and earnings disclosures.